A Key Link for Transmission Prevention

HIV Clinical Trial

— MP3  

Official title:

Acute HIV Infection - A Key Link for Transmission Prevention: A Randomized Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01450189
• Other study ID #: 11-0815
• Secondary ID: CID 1002
• Status: Completed
• Phase: N/A
• First received: September 18, 2011
• Last updated: April 17, 2018
• Start date: October 2011
• Est. completion date: July 2014

Study information

• Verified date: November 2016
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study will assess the feasibility for the potential public health benefit of behavioral and antiretroviral interventions during acute HIV infection.

Central Hypothesis The investigators hypothesize that delivering behavioral and antiretroviral interventions to acutely infected persons will reduce onward transmission.

Description:

The HIV epidemic in sub-Saharan Africa is severe and continues to grow. In urban areas of Malawi, 19% of pregnant women seeking antenatal care and 15.6% of Malawians aged 15-49 years were infected with HIV in 2007. Prevention interventions that prevent onward transmission of HIV are urgently needed.

Persons with acute HIV infection (AHI) may be responsible for a substantial proportion of onward transmission of HIV infection. AHI is characterized by unfettered replication of HIV in a "ramp up viremia". The high concentration of HIV in blood and genital secretions remains elevated for up to 10-12 weeks before it declines to the levels observed in established infection. These high levels of HIV shedding in the genital tract are likely to produce very efficient sexual transmission and the proportion of virions that are infectious may be substantially higher during acute compared to chronic infection. Consequently, the probability of transmission during unprotected intercourse for those with AHI is very high. Identifying persons with AHI and intervening to reduce onward transmission represents a tantalizing, but unproven, opportunity for HIV prevention.

To have maximal impact, a prevention program targeting AHI must identify a substantial number of acutely infected persons and intervene quickly to minimize onward transmission. An effective immediate intervention would require behavioral modification to limit sexual partners and unprotected sex acts, and a biological intervention to reduce infectious viral burden in genital secretions. This is the first study to pilot a combined behavioral and biomedical intervention in individuals with AHI to reduce onward transmission of HIV.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Primary participants:

• Acute HIV-1 infection

• Men and women age greater than/= 18 years.

• Intention to remain in the Lilongwe area for the duration of the study.

• Ability and willingness of participant to provide informed consent.

• Willingness to provide contact/locator information, be contacted, and asked to return for AHI results.

Partner Participants:

• Referred by a primary participant and present with a referral card.

• Had vaginal or anal sex with a primary participant within 12 weeks prior to that primary participant's enrolling

• Men and women age greater than/=18 years.

• remain in the Lilongwe area for the duration of the study.

• Ability and willingness of participant to provide informed consent.

Exclusion Criteria:

Primary Participants:

• HIV infection based on two positive HIV antibody rapid tests at the time of screening.

• HIV-negative based on one or more antibody rapid test and an HIV RNA PCR test.

• Serious illness, including tuberculosis or opportunistic infection, requiring systemic treatment and/or hospitalization.

• Active drug or alcohol use or dependence.

• Current imprisonment or involuntary incarceration.

• Any other condition that in the opinion of the study investigator would compromise the safety of the study participant or study staff, or would prevent proper conduct of the study.

Partner Participants:

• Active drug or alcohol use or dependence.

• Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness.

Exclusion for Receipt of Antiretroviral Drugs in the BIA Arm

Note:A key component of this pilot study is to estimate the potential effect of ARVs during acute infection when applied on a large population scale.In effect, this pilot study should be viewed as a pilot for an effectiveness trial. Consequently, we will randomize all eligible participants to one of the three arms. If, however, persons should not receive ARVs for a variety of medically-related reasons, these persons will remain in the BIA arm, but will not receive ARVs. Women who are of reproductive potential but who refuse to use at least one form of contraception (see below), will remain in the BIA arm but will not receive ARVs. Similarly, persons randomized to the BI arm who do not attend all sessions will remain in the BI arm.

Persons randomized to BIA with any of the following conditions will be excluded from receiving ARVs, but will remain in the BIA group for purposes of analysis.

• Laboratory values obtained at Day 0 prior to initiating ARVs at a subsequent visit

• Absolute neutrophil count <300/mm3

• Hemoglobin <8.0 g/dL

• Platelet count <40,000/mm3

• Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase > 5 x upper limit of normal (ULN)

• Total bilirubin >2.5 x ULN

• Creatinine Clearance (CrCl) <60 mL/min

• Hepatitis B surface antigen positivity

• Positive serum or urine pregnancy test at Day 0.

• Breastfeeding

• Refusal to use at least one method of contraception, if a woman is of reproductive potential.

Acceptable forms of contraception include: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, intrauterine device (IUD), or a hormonal-based contraceptive.

Women not meeting the reproductive potential criteria above may receive the study drugs without using contraception.

• Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.

• Requirement for any current medications that are prohibited with any study drugs.

Related Conditions & MeSH terms

• HIV

Intervention

Behavioral:
• Standard HIV prevention messages
A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
• BI: Information-Motivation-Behavioral Skills Model
The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.

Drug:
• Raltegravir
raltegravir (400 mg) administered orally twice daily for 12 weeks
• emtricitabine/tenofovir disoproxil fumarate
emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks

Locations

Country	Name	City	State
Malawi	Lighthouse Trust, Kamuzu Central Hospital	Lilongwe
Malawi	UNC Project	Lilongwe

Sponsors (1)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

Malawi, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening		1 year
Primary	Prevalence of AHI Among Persons Screened	Prevalence of AHI among all persons screened. This measure is among all persons screened, prior to randomization.	1 year
Primary	Proportion of Persons With AHI Successfully Recruited Into the Study	This outcome reflects the ability to recruit persons with AHI into a study. The outcome is based on the population prior to randomization.	1 year
Primary	Proportion of Participants Completing Full Course of ARVs in Arm BIA	Proportion of participants in the BIA arm receiving full course of ARVs. This outcome is calculated among the BIA arm only, as that	1 year
Primary	Proportion of Participants in Arm BI and BIA (Combined) Who Complete the 4 Behavioral Sessions Within 3 Weeks of Enrollment.	In this pilot study, we addressed our ability to complete the behavioral intervention quickly. As two arms received the behavioral intervention, this outcome is combined across those two arms.	1 year
Primary	Proportion of Persons Completing All Scheduled Visits in Each Study Arm		1 year
Primary	Number of Adverse Events	Mean number of adverse events per group	one year
Secondary	Unprotected Sex Acts in Previous One Week - 12 Weeks	The mean number of unprotected sex acts in previous one week, assessed at 12 weeks	12 weeks
Secondary	Unprotected Sex Acts in Previous One Week - 26 Weeks	The mean number of unprotected sex acts in previous one week, assessed at 26 weeks	26 weeks
Secondary	Unprotected Sex Acts in Previous One Week - 52 Weeks	The mean number of unprotected sex acts in previous one week, assessed at 52 weeks	52 weeks
Secondary	Unprotected Sex Acts in Previous One Month - 12 Weeks	The mean number of unprotected sex acts in previous one month, assessed at 12 weeks	12 weeks
Secondary	Unprotected Sex Acts in Previous One Month - 26 Weeks	The mean number of unprotected sex acts in previous one month, assessed at 26 weeks	26 weeks
Secondary	Unprotected Sex Acts in Previous One Month - 52 Weeks	The mean number of unprotected sex acts in previous one month, assessed at 52 weeks	52 weeks
Secondary	Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite)	Cumulative incidence, definied as at least one incident infection with either gonorrhea, chlamydia or trichomoniasis	26 weeks
Secondary	Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite)	At least one incident infection with either gonorrhea, chlamydia or trichomoniasis	52 weeks
Secondary	Cumulative Incidence Herpes Simplex Virus Type 2	cumulative incidence of herpes simplex virus type 2, assessed at 26 weeks. Persons with baseline positivity were excluded.	26 weeks
Secondary	Cumulative Incidence Herpes Simplex Virus Type 2	cumulative incidence of herpes simplex virus type 2, assessed at 52 weeks. Persons with baseline positivity were excluded.	52 weeks
Secondary	Number of Partners Reporting for HIV Testing	Number of partners per index reporting for HIV testing at any time during follow-up	52 weeks
Secondary	Proportion of Partners Reporting for HIV Testing	Proportion of sexual partners reporting for HIV testing among all sexual partners named by the index participants	52 weeks
Secondary	Suppression of HIV RNA to <1000c/ml at 12 Weeks	Proportion of persons in each arm with viral load <1000copies/ml at 12 weeks	12 weeks
Secondary	Time to HIV RNA Suppression <1000 c/ml	median time to viral load suppression (<1000 c/ml)	From date of randomization until viral load suppression, up to 52 weeks
Secondary	Blood HIV RNA Concentration at Week 12		12 weeks
Secondary	Blood HIV RNA Concentration at Week 26		26 weeks
Secondary	Blood HIV RNA Concentration at Week 52		52 weeks
Secondary	Genital HIV RNA Concentration - Week 12, Women	median HIV RNA concentration in cervical lavage fluid	12 weeks
Secondary	Genital HIV RNA Concentration - Week 26, Women	median HIV RNA concentration in cervical lavage fluid	26 weeks
Secondary	Genital HIV RNA Concentration - Week 52, Women	median HIV RNA concentration in cervical lavage fluid	52 weeks
Secondary	Genital HIV RNA Concentration - Week 12, Men	median HIV RNA concentration as measured in semen	12 weeks
Secondary	Genital HIV RNA Concentration - Week 26, Men	median HIV RNA concentration as measured in semen	26 weeks
Secondary	Genital HIV RNA Concentration - Week 52, Men	median HIV RNA concentration as measured in semen	52 weeks